Head-To-Head Comparison: Baxter International (NYSE:BAX) and Resonate Blends (OTCMKTS:KOAN)

Resonate Blends (OTCMKTS:KOAN) and Baxter International (NYSE:BAX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations and valuation.

Risk and Volatility

Resonate Blends has a beta of 3.11, meaning that its share price is 211% more volatile than the S&P 500. Comparatively, Baxter International has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500.

Institutional and Insider Ownership

7.4% of Resonate Blends shares are owned by institutional investors. Comparatively, 90.2% of Baxter International shares are owned by institutional investors. 50.0% of Resonate Blends shares are owned by insiders. Comparatively, 0.2% of Baxter International shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Resonate Blends and Baxter International’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Resonate Blends	-89.79%	N/A	-121.01%
Baxter International	-4.71%	17.24%	5.12%

Valuation and Earnings

This table compares Resonate Blends and Baxter International”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Resonate Blends	$1.90 million	0.25	-$2.13 million	($0.02)	-0.12
Baxter International	$10.64 billion	1.45	-$649.00 million	($1.10)	-27.28

Resonate Blends has higher earnings, but lower revenue than Baxter International. Baxter International is trading at a lower price-to-earnings ratio than Resonate Blends, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Resonate Blends and Baxter International, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Resonate Blends	0	0	0	0	0.00
Baxter International	1	3	5	0	2.44

Baxter International has a consensus target price of $37.25, suggesting a potential upside of 24.14%. Given Baxter International’s stronger consensus rating and higher possible upside, analysts clearly believe Baxter International is more favorable than Resonate Blends.

Summary

Baxter International beats Resonate Blends on 9 of the 14 factors compared between the two stocks.

About Resonate Blends

Resonate Blends, Inc., a cannabis holding company, provides cannabis wellness lifestyle products. The company offers Calm to quiet the mind and ease into a gentle sense of wellbeing; Wonder, a THC offering to bring back the youthful sense; Love to reduce barriers to intimacy, stimulate personal connections, and increase tactile sensation; Create to stimulate senses, spark imagination, and channel inner muse; Play to become fully immersed in the moment and the people around; Delight to open up senses; and Sleep for helping to fall asleep. The company was formerly known as Textmunication Holdings, Inc. and changed its name to Resonate Blends, Inc. in December 2019. Resonate Blends, Inc. is based in Calabasas, California.

About Baxter International

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company’s products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors’ offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.